›› 2011, Vol. 31 ›› Issue (2): 208-.doi: 10.3969/j.issn.1674-8115.2011.02.020

• Original article (Clinical research) • Previous Articles     Next Articles

Effects of different applications of statins on ICAM-1, VCAM-1 and MCP-1 in patients with coronary heart diseases

LIANG Wei1, WU Chun-fang2, YANG Hui3, YU Qiang3, ZHANG Da-dong3, LU Guo-ping2   

  1. 1.Department of Gerontology, 2.Department of Cardiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China；3.Department of Cardiology, Central Hospital of Minhang District, Ruijin Hospital Group, Shanghai 201100, China
  • Online:2011-02-28 Published:2011-03-01

PDF (PC)

2015

Abstract:

Objective To investigate the effects of different applications of statins on intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1) in patients with coronary heart diseases. Methods Forty-two patients with coronary heart disease (coronary artery stenosis between 50% and 70%) without stent implantation were divided into monotherapy group (n=19) and combined therapy group (n=23). Patients in monotherapy group were treated with 20 mg atorvastatin from the first week to the fourth week, and were managed with 50 mg atorvastatin from the fifth week to the twelfth week. Patients in combined therapy group were treated with 5 mg atorvastatin+10 mg ezetimibe from the first week to the fourth week, and were managed with 10 mg atorvastatin+10 mg ezetimibe from the fifth week to the twelfth week. Blood samples were collected before treatment and 4 weeks and 12 weeks after treatment, and blood lipid, liver and renal function and concentrations of creatine kinase, ICAM-1, VCAM-1 and MCP-1 were measured. Results The concentrations of TC and LDL-C in monotherapy group and combined therapy group significantly decreased 4 weeks after treatment, and the concentrations of TC and LDL-C 12 weeks after treatment were significantly lower than those before treatment (decreased by 37.82% and 38.26%, respectively)(P<0.01). However, there was no significant difference between these two groups (P>0.05). There was no significant increase in liver and renal function and concentration of creatine kinase after treatment in these two groups. Twelve weeks after treatment, the concentrations of ICAM-1, VCAM-1 and MCP-1 in monotherapy group were significantly lower than those before treatment, and there were significant differences between monotherapy group and combined therapy group (P<0.05). Conclusion Monotherapy with larger dose of statins may be superior to combined therapy with smaller dose of statins and ezetimibe in plaque stabilization in patients with coronary heart diseases.

Key words: atorvastatin, ezetimibe, lipid decrease, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, monocyte chemoattractant protein-1